1. ScholarBank@NUS

Yan Li Natalie Ngoi

rp66158

Collaboration Map View Statistics Email Alert RSS Feed

Profile

Full Name
Yan Li Natalie Ngoi
Main Affiliation
 
Faculty
 
Email
mdcylnn@nus.edu.sg
 

Publications

Refined By:
File Format:  Adobe PDF

Results 1-14 of 14 (Search time: 0.009 seconds).

Issue DateTitleAuthor(s)
12020A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)Lee, Yong Jae; Lim, Myong Cheol; Kim, Byoung-Gie; Ngoi, Natalie YL ; Choi, Chel Hun; Park, Sang-Yoon; Tan, David SP ; Go, Yunjung; Lee, Jung-Yun
21-Dec-2019Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypesTan, Tuan Zea ; Ye, Jieru ; Yee, Chung Vin ; Lim, Diana; Ngoi, Natalie Yan Li ; Tan, David Shao Peng; Huang, Ruby Yun-Ju 
3Jun-2021Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promisesPham, Melissa M; Ngoi, Natalie YL ; Peng, Guang; Tan, David SP ; Yap, Timothy A 
41-Aug-2020Exploiting replicative stress in gynecological cancers as a therapeutic strategyNgoi, Natalie YL ; Sundararajan, Vignesh; Tan, David SP
529-Jun-2021PD-L1 Expressing Recurrent Clear Cell Carcinoma of the Vulva with Durable Partial Response to Pembrolizumab: A Case ReportSachdeva, Manavi; Ngoi, Natalie YL ; Lim, Diana ; Poon, Michelle LM ; Thian, Yee Liang ; Lim, Yi Wan; Lim, Siew Eng ; Tong, Pearl ; Lum, Jeffrey HY ; Ng, Joseph ; Ilancheran, Arunachalam ; Domingo, Efren J; Low, Jeffrey JH ; Tan, David SP 
61-Jun-2022Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor–Positive Breast CancerLim, JSJ ; Wong, ALA ; Ow, SGW ; Ngoi, NYL ; Chan, GHJ; Ang, YLE; Chong, WQ; Lim, SE ; Lim, YW; Lee, M; Choo, JRE; Tan, HL; Yong, WP ; Soo, RA ; Tan, DSP ; Chee, CE ; Sundar, R ; Yadav, K ; Jain, S ; Wang, L ; Tai, BC ; Goh, BC ; Lee, SC 
714-Jun-2022Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis InhibitorsChoo, Joan RE; Jan, Yi-Hua; Ow, Samuel GW ; Wong, Andrea ; Lee, Matilda Xinwei; Ngoi, Natalie ; Yadav, Kritika ; Lim, Joline SJ ; Lim, Siew Eng ; Chan, Ching Wan ; Hartman, Mikael ; Tang, Siau Wei ; Goh, Boon Cher ; Tan, Hon Lyn; Chong, Wan Qin; Yvonne, Ang Li En; Chan, Gloria HJ; Chen, Shu-Jen; Tan, Kien Thiam; Lee, Soo Chin 
82018Study protocol: Phase 1 dose escalating study of pressurized intraperitoneal aerosol chemotherapy (PIPAC) with oxaliplatin in peritoneal metastasisKim, G.; Tan, H.L.; Chen, E.; Teo, S.C. ; Jang, C.J.M. ; Ho, J. ; Ang, Y.; Ngoi, N.Y.L. ; Chee, C.E.; Lieske, B.; Shabbir, A.; Wang, L.-Z.; So, J.B.Y. ; Yong, W.P. 
9Jun-2021Targeting the replication stress response through synthetic lethal strategies in cancer medicineNgoi, Natalie YL ; Pham, Melissa M; Tan, David SP ; Yap, Timothy A 
101-Mar-2019The 4th European Society for Medical Oncology Asia Congress: bridging ultimate cancer care with real-world practice for the Asian practitioner in gynecological cancersNgoi, Natalie YL ; Tan, David SP
1117-Jun-2021The redox-senescence axis and its therapeutic targetingNgoi, Natalie YL ; Liew, Angeline QX; Chong, Stephen JF ; Davids, Matthew S ; Clement, Marie-Veronique ; Pervaiz, Shazib 
12Aug-2021The Role of Molecular Tests for Adjuvant and Post-Surgical Treatment in Gynaecological CancersWijaya, Silvana Talisa; Ngoi, Natalie YL ; Tan, David SP
131-Dec-2023Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4Kim, YN; Park, B; Kim, JW; Kim, BG; Kim, SW; Kim, HS; Choi, CH; Lim, MC; YL Ngoi, N ; SP Tan, D ; Lee, JY
141-Mar-2017Update on immune checkpoint inhibitors in gynecological cancersHeong, Valerie; Ngoi, Natalie ; Tan, David Shao Peng